Skip to main content
SpringerLink
Log in

Seizures in Multisystem Disease Affecting the Nervous System

  • Chapter
Seizures

Part of the book series: Current Clinical Neurology ((CCP))

  • 328 Accesses

Abstract

This chapter discusses a heterogeneous group of disorders that involve the central nervous system (CNS) and cause seizures (Table 1). Nervous system involvement is part of the disease definition or is a complication of the systemic disease process. Neurologic manifestations, including seizures, can present before the systemic illness becomes manifest but more commonly occur in the setting of established disease. Seizures can also be a complication of end-organ damage caused by the underlying illness, or of medications used to treat the illness. The incidence of neurologic complications and seizures varies widely. The etiopathogenesis of seizures is mostly unknown in this diverse group of diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. McCune WJ, Golbus J. Neuropsychiatric lupus. Rheum Dis Clin North Am 1988; 14: 149–167.

    PubMed  CAS  Google Scholar 

  2. Janssen BA, Bruyn GAW. Nervous system involvement in systemic lupus erythematosis, including the antiphospholipid antibody syndrome. In Aminoff MJ, Goetz CG (eds.), Handbook of Clinical Neurology. Amsterdam: Elsevier Science, 1998, vol 71, pp 35–58.

    Google Scholar 

  3. Kovacs JAJ, Urowitz MB, Gladman DD. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 1993; 19: 795–814.

    PubMed  CAS  Google Scholar 

  4. Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GRV. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosis. Arthritis Rheum 1994; 37: 568–571.

    Article  PubMed  CAS  Google Scholar 

  5. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB. Association between lupus psychosis and anti-ribosomal-P antibodies. New Engl J Med 1987; 317: 265–271.

    Article  PubMed  CAS  Google Scholar 

  6. Golombek SJ, Graus F, Elkon KB. Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 1090–1097.

    Article  PubMed  CAS  Google Scholar 

  7. Mevorach D, Elkon KB. Neuropsychiatric lupus: getting beyond the barrier of the brain. (editorial) Lupus 1996; 5: 173–174.

    Article  PubMed  CAS  Google Scholar 

  8. Toubi E, Khamashta MA, Panarra A, Hughes GRV. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythmatosus. Am J Med 1995; 99: 397–401.

    Article  PubMed  CAS  Google Scholar 

  9. Hughes GRV. Anticardiolipin antibodies: risk factor for venous and arterial thrombosis. Lancet 1985; 1: 912.

    Google Scholar 

  10. Verrot D, San-Marco M, Dravet C, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103: 33–37.

    Article  PubMed  CAS  Google Scholar 

  11. Liou HH, Wang CR, Chen CJ, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5: 307–312.

    Article  PubMed  CAS  Google Scholar 

  12. Ford RG, Siekert RG. Central nervous system manifestations of periarteritis nodosa. Neurology 1965; 15: 114–122.

    Article  PubMed  CAS  Google Scholar 

  13. Moore PM, Fauci AS. Neurologic manifestations of systemic vasculitis.Am J Med 1981;71:517–524.

    Google Scholar 

  14. Tervaert JWC, Kallenberg C. Neurologic manifestations of systemic vasculitis. Rheum Dis Clin North Am 1993; 19: 913–940.

    PubMed  CAS  Google Scholar 

  15. Drachman DD. Neurological complications of Wegener’s granulomatosis.Arch Neurol 1963;8:145–155.

    Google Scholar 

  16. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76–85.

    PubMed  CAS  Google Scholar 

  17. Nishino H, Rubino FA, DeRemee RA, Swanson JW, Parisi JE. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33: 4–9.

    Article  PubMed  CAS  Google Scholar 

  18. Nishino H, Rubino FA, Parisi JE. The spectrum of neurologic involvement in Wegener’s granulomatosis. Neurology 1993; 43: 1334–1337.

    Article  PubMed  CAS  Google Scholar 

  19. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behcet’s disease. Semin Arthritis Rheum 1998; 27: 197–217.

    Article  PubMed  CAS  Google Scholar 

  20. Goodin DS. Behcet’s disease. In Aminoff MJ, Goetz CG (eds.), Handbook of Clinical Neurology. Amsterdam: Elsevier Science, 1998, vol 71, pp 209–231.

    Google Scholar 

  21. Al-Dalaan AN, Al Balaa SR, El Ramahi K, et al. Behcet’s disease in Saudi Arabia. J Rheumatol 1994; 21: 658–661.

    PubMed  CAS  Google Scholar 

  22. Aron AM, Freemen JM, Carter S. The natural history of Sydenham’s chorea: a review of the literature and long-term evaluation with emphasis on cardiac sequelae. Am J Med 1965; 38: 83–95.

    Article  PubMed  CAS  Google Scholar 

  23. Ch’ien LT, Economides AN, Lemmi H Sydenham’s chorea and seizures. Arch Neurol 1978; 35: 382–385.

    Article  PubMed  Google Scholar 

  24. Nausieda PA, Grossman BJ, Koller WC, Weiner WJ, Klawans HL. Sydenham’s chorea: an update. Neurology 1980; 30: 331–334.

    Article  PubMed  CAS  Google Scholar 

  25. Krumholz A, Stern BJ. Neurological manifestations of sarcoidosis. In: Aminoff MJ, Goetz CG (eds.), Handbook of Clinical Neurology. Amsterdam: Elsevier Science, 1998, vol 71, pp 463–499.

    Google Scholar 

  26. Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993; 43: 8–12.

    Article  PubMed  CAS  Google Scholar 

  27. Stern BJ, Krumholz A, Johns C, Scott P, Nissim J. Sarcoidosis and its neurological manifestations. Arch Neurol 1985; 42: 909–917.

    Article  PubMed  CAS  Google Scholar 

  28. Krumholz A, Stern B, Stern EG. Clinical implications of seizures in neurosarcoidosis. Arch Neurol 1991; 48: 842–844.

    Article  PubMed  CAS  Google Scholar 

  29. Pentland B, Mitchell JD, Cull RE, Ford MJ. Central nervous system sarcoidosis. Q J Med New Series 1985; 220: 457–465.

    Google Scholar 

  30. Delaney P. Seizures in sarcoidosis: a poor prognosis. Ann Neurol 1980; 7: 494.

    Article  PubMed  CAS  Google Scholar 

  31. Luke RA, Stern B, Krumholz A, Johns CJ. Neurosarcoidosis: the long-term clinical course. Neurology 1987; 37: 461–463.

    Article  PubMed  CAS  Google Scholar 

  32. Nishizaki T, Iwamoto F, Uesugi, Akimura T, Yamashita K, Ito H. Idiopathic cranial pachymeningoencephalitis focally affecting the parietal dura mater and adjacent brain parenchyma: case report. Neurosurgery 1997; 40: 840–843.

    Article  PubMed  CAS  Google Scholar 

  33. Lorish TR, Thorsteinsson G, Howard FM. Stiff-man syndrome updated. Mayo Clin Proc 1989; 64: 629–636.

    PubMed  CAS  Google Scholar 

  34. McEvoy KM. Stiff-man syndrome. Mayo Clin Proc 1991; 66: 300–304.

    PubMed  CAS  Google Scholar 

  35. Solimena M, Folli F, Denis-Donini S, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med 1988; 318: 1012–1020.

    Article  PubMed  CAS  Google Scholar 

  36. Solimena M, Folli F, Aparisi R, Pozza G, DeCamilli P. Autoantibodies to GABAergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990; 322: 1555–1560.

    Article  PubMed  CAS  Google Scholar 

  37. Martinelli P, Pazzaglia P, Montagna P, et al. Stiff-man syndrome associated with nocturnal myoclonus and epilepsy. J Neurol Neurosurg Psychiatry 1978; 41: 458–462.

    Article  PubMed  CAS  Google Scholar 

  38. Grimaldi LME, Martino G, Braghi S, et al. Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol 1993; 34: 57–64.

    Article  PubMed  CAS  Google Scholar 

  39. Folli F, Solimena M, Cofiell R, et al. Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993; 328: 546–551.

    Article  PubMed  CAS  Google Scholar 

  40. Alexander EL, Provost TT, Stevens MB, Alexander GE. Neurologic complications of primary Sjt gren’s syndrome. Medicine 1982; 61: 247–257.

    Article  PubMed  CAS  Google Scholar 

  41. Alexander E. Central nervous system disease in Sjogren’s syndrome: new insights into immunopathogenesis. Rheum Dis Clin North Am 1992; 18: 637–672.

    PubMed  CAS  Google Scholar 

  42. Alexander EL. Neurologic disease in Sjogren’s syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. Rheum Dis Clin North Am 1993; 19: 869–908.

    CAS  Google Scholar 

  43. Bathon JM, Moreland LW, DiBartolomeo AG. Inflammatory central nervous system involvement in rheumatoid arthritis. Semin Arthritis Rheum 1989; 18: 258–266.

    Article  PubMed  CAS  Google Scholar 

  44. Gupta VP, Ehrlich GE. Organic brain syndrome in rheumatoid arthritis following corticosteroid withdrawal. Arthritis Rheum 1976; 19: 1333–1338.

    Article  PubMed  CAS  Google Scholar 

  45. Beck DO, Corbett JJ. Seizures due to central nervous system rheumatoid meningovasculitis. Neurology 1983; 33: 1058–1061.

    Article  PubMed  CAS  Google Scholar 

  46. Ouyang R, Mitchell DM, Rozdilsky B. Central nervous system involvement in rheumatoid disease. Neurology 1967; 17: 1099–1105.

    Article  PubMed  CAS  Google Scholar 

  47. Hietaharju A, Jââskelâinen S, Hietarinta M, Frey H. Central nervous system involvement and psychiatric manifestations in systemic sclerosis (sleroderma): clinical and neurophysiological evaluation. Acta Neurol Scand 1993; 87: 382–387.

    PubMed  CAS  Google Scholar 

  48. Pathak R, Gabor M. Scleroderma and central nervous system vasculitis. Stroke 1991; 22: 410–413.

    Article  PubMed  CAS  Google Scholar 

  49. Chung MH, Sum J, Morrell MJ, Horoupian DS. Intracerebral involvement in scleroderma en coup de sabre: report of a case with neuropathologic findings. Ann Neurol 1995; 37: 679–681.

    Article  PubMed  CAS  Google Scholar 

  50. Pavlakis SG, Phillips PC, DiMauro S, DeVivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984; 16: 481–488.

    Article  PubMed  CAS  Google Scholar 

  51. DiMauro S, Moraes CT. Mitochondrial encephalomyopathies. Arch Neurol 1993; 50: 1197–1208.

    Article  PubMed  CAS  Google Scholar 

  52. DiMauro S. Mitochondrial encephalomyopathies. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Kunkel LM (eds.), The Molecular and Genetic Basis of Neurological Disease. Boston, MA: Butterworth-Heineman, 1993, pp 665–694.

    Google Scholar 

  53. Ciafaloni E, Ricci E, Shanske S, et al. MELAS: Clinical features, biochemistry, and molecular genetics. Ann Neurol 1992; 31: 391–398.

    Article  PubMed  CAS  Google Scholar 

  54. Kuzniecky R. Symptomatic occipital lobe epilepsy. Epilepsia 1998; 39 (Suppl 4): 24–31.

    Article  Google Scholar 

  55. Graeber MB, Müller U. Recent developments in the molecular genetics of mitochondrial disorders. J Neurol Sci 1998; 153: 251–263.

    Article  PubMed  CAS  Google Scholar 

  56. So N, Berkovic S, Andermann F, Kuzniecky R, Gendron D, Quesney LE Myoclonic epilepsy and ragged red fibres (MERRF). Electrophysiological studies and comparison with other progressive myoclonic epilepsies. Brain 1989; 112: 1261–1276.

    Article  PubMed  Google Scholar 

  57. DiMauro S. Genetic heterogeneity in Leigh syndrome. Ann Neurol 1996; 40: 5–6.

    Article  PubMed  CAS  Google Scholar 

  58. Morris AAM, Leonard JV, Brown GK, et al. Deficiency of respiratory chain complex I is a common cause of Leigh disease. Ann Neurol 1996; 40: 25–30.

    Article  PubMed  CAS  Google Scholar 

  59. Rahman S, Blok RB, Dahl H-HM, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996; 39: 343–351.

    Article  PubMed  CAS  Google Scholar 

  60. Holt IJ, Harding AE, Petty RKH, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46: 428–433.

    PubMed  CAS  Google Scholar 

  61. Mâkelâ-Bengs P, Suomalainen A, Majander A, et al. Correlation between the clinical symptoms and the proportion of mitochondrial DNA carrying the 8993 point mutation in the NARP syndrome. Ped Res 1995; 37: 634–639.

    Article  Google Scholar 

  62. Rowland LP, Hays AP, DiMauro S. Diverse clinical disorders associated with morphological abnormalities of mitochondria. In: Cerri C, Scarlato G (eds.), Mitochondrial pathology in muscle diseases. Padua: Piccin Editore, 1983, pp 141–158.

    Google Scholar 

  63. Huttenlocher PR, Trauner DA. Reye’s syndrome. In: Vinken PJ, Bruyn GW (eds.), Handbook of Clinical Neurology. Amsterdam: North-Holland, 1977, vol 29, pp 331–344.

    Google Scholar 

  64. Davis LE, Woodfin BM. Reye’s syndrome. In: Goetz CG, Aminoff MJ (eds.), Handbook of Clinical Neurology. Amsterdam: Elsevier Science, 1998, vol 70, pp 267–298.

    Google Scholar 

  65. Bonkowsky HL, Schady W. Neurologic manifestations of acute porphyria. Semin Liver Dis 1982; 2: 108–124.

    Article  PubMed  CAS  Google Scholar 

  66. Bylesjo I, Forsgren L, Lithner F, Boman K. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia 1996; 37: 230–235.

    Article  PubMed  CAS  Google Scholar 

  67. Reynolds NC, Miska RM. Safety of anticonvulsants in hepatic porphyrias. Neurology 1981; 31: 480–484.

    PubMed  Google Scholar 

  68. Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF. Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology 1980; 30: 588–592.

    Article  PubMed  CAS  Google Scholar 

  69. Tatum WO, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995; 45: 1216–1217.

    Article  PubMed  Google Scholar 

  70. Thomas JE, Ayyar DR. Systemic fat embolism: a diagnostic profile in 24 patients. Arch Neurol 1972; 26: 517–523.

    Article  PubMed  CAS  Google Scholar 

  71. Jacobson DM, Terrence CF, Reinmuth OM. The neurologic manifestations of fat embolism. Neurology 1986; 36: 847–851.

    Article  PubMed  CAS  Google Scholar 

  72. Pell ACH, Hughes D, Keating J, Christie J, Busuttil A, Sutherland G. Brief report: fulminating fat embolism syndrome caused by paradoxical embolism through a patent foramen ovale. N Engl J Med 1993; 329: 926–929.

    Article  PubMed  CAS  Google Scholar 

  73. Scopa M, Magatti M, Rossitto P. Neurologic symptoms in fat embolism syndrome: case report. Trauma 1994; 36: 906–908.

    Article  CAS  Google Scholar 

  74. Hofmann S, Huemer G, Salzer M. Pathophysiology and management of the fat embolism syndrome. Anaesthesia 1998; 53 (Suppl 2): 35–37.

    Article  PubMed  Google Scholar 

  75. Dick APK, Massey EW. Neurologic presentation of decompression sickness and air embolism in sport divers. Neurology 1985; 35: 667–671.

    Article  PubMed  CAS  Google Scholar 

  76. Aita JA. Neurologic manifestations of dysbarism. In: Vincken PJ, Bruyn GW (eds.), Handbook of Clinical Neurology. Amsterdam: North-Holland, 1972, vol 12, pp 665–676.

    Google Scholar 

  77. Gillen HW. Air embolism. In: Vinken PJ, Bruyn GW (eds.), Handbook of Clinical Neurology. Amsterdam: North-Holland, 1975, vol 23, pp 609–629.

    Google Scholar 

  78. O’Brien JL, Sibley WA. Neurologic manifestations of thrombotic thrombocytopenic purpura. Neurology 1958; 8: 55–64.

    Article  PubMed  Google Scholar 

  79. Amorosi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966; 45: 139–159.

    Article  Google Scholar 

  80. Silverstein A. Thrombotic thrombocytopenic purpura. The initial neurologic manifestations. Arch Neurol 1968; 18: 358–362.

    Article  PubMed  CAS  Google Scholar 

  81. Ridolfi RL, Bell WR. Thrombotic thrombocytopenic purpura. Report of 25 cases and review of the literature. Medicine 1981; 60: 413–428.

    Article  PubMed  CAS  Google Scholar 

  82. Garrett WT, Chang CWJ, Bleck TP. Altered mental status in thrombotic thrombocytopenic purpura is secondary to nonconvulsive status epilepticus. Arch Neurol 1996; 40: 245–246.

    Article  CAS  Google Scholar 

  83. Blum AS, Drislane FW. Nonconvulsive status epilepticus in thrombotic thrombocytopenic purpura. Neurology 1996;47:1079–1081

    Google Scholar 

  84. Greer M, Schotland D. Abnormal hemoglobin as a cause of neurologic disease. Neurology 1962; 12: 114–123.

    Article  PubMed  CAS  Google Scholar 

  85. Portnoy BA, Herion JC. Neurologic manifestations in sickle cell disease. Ann Internal Med 1972; 76: 643–652.

    CAS  Google Scholar 

  86. Fabian RH, Peters BH. Neurologic complications of hemoglobin SC disease. Ann Neurol 1984; 41: 289–292.

    Article  CAS  Google Scholar 

  87. Liu JE, Gzech DJ, Ballas SK. The spectrum of epilepsy in sickle cell anemia. J Neurol Sci 1994; 123: 6–10.

    Article  PubMed  CAS  Google Scholar 

  88. Ramaiah C, Boynton RF. Whipple’s disease. Gastroenterol Clin North Am 1998; 27: 683–695.

    CAS  Google Scholar 

  89. Riggs JE, Schochet SS. Neurological dysfunction in Whipple disease. In: Goetz CG, Aminoff MJ (eds.), Handbook of Clinical Neurology. Amsterdam: Elsevier Science, 1998, vol 70, pp 239–248.

    Google Scholar 

  90. Louis ED, Lynch T, Kaufmann P, Fahn S, Odel J. Diagnostic guidelines in central nervous system Whipple’s disease. Ann Neurol 1996; 40: 561–568.

    Article  PubMed  CAS  Google Scholar 

  91. Lynch T, Odel J, Fredericks DN, et al. Polymerase chain reaction-based detection of Tropheryma whippelii in central nervous system Whipple’s disease. Ann Neurol 1997; 42: 120–124.

    Article  PubMed  CAS  Google Scholar 

  92. Delanty N, Georgescu L, Lynch T, Paget S, Stübgen J-P. Synovial fluid polymerase chain reaction as an aid to the diagnosis of central nervous system Whipple’s disease. Ann Neurol 1999; 45: 137–138.

    Article  PubMed  CAS  Google Scholar 

  93. Knox DL, Green WR, Troncoso JC, Yardley JH, Hsu J, Zee DS. Cerebral ocular Whipple’s disease: a 62-year odyssey from death to diagnosis. Neurology 1995; 45: 617–625.

    Article  PubMed  CAS  Google Scholar 

  94. Schnider PJ, Reisiger EC, Gerschlager W. Long-term follow-up in cerebral Whipple’s disease. Eur J Gastroenterol Hepatol 1996; 8: 899–903.

    PubMed  CAS  Google Scholar 

  95. Schnider PJ, Reisinger EC, Berger T, Krejs GJ, Auff E. Treatment guidelines in central nervous system Whipple’s disease. Ann Neurol 1997; 41: 561–562.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Joerg-Patrick Stübgen MD, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Clinical Neurological Sciences, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland

    Norman Delanty MB, FRCPI (Consultant Neurologist) (Consultant Neurologist)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media New York

About this chapter

Cite this chapter

Stübgen, JP. (2002). Seizures in Multisystem Disease Affecting the Nervous System. In: Delanty, N. (eds) Seizures. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-094-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-094-0_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-207-0

  • Online ISBN: 978-1-59259-094-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation